Research News for June 2010
-
Lack of Insurance Affects African Americans’ Breast Cancer Prognosis More Than Whites’
Research suggests that having no or inadequate health insurance makes a bigger difference in breast cancer prognosis for African American women compared to white women.
-
Optical Tomography May Help Assess Suspicious Areas in Breast
Research suggests that optical tomography may be able to help determine if a suspicious area in the breast is cancer or not.
-
Oral Bisphosphonates May Reduce Risk for Postmenopausal Women
Two studies suggest that oral bisphosphonates may reduce the risk of invasive breast cancer in postmenopausal women by 30% to 40%.
-
Some Parents Who’ve Been Tested Support Abnormal Breast Cancer Gene Testing for Kids
About a third of people who were tested for abnormal breast cancer genes (BRCA1 or BRCA2), supported the same testing for their children.
-
New Technique May Find Heart Damage Earlier
Research suggests that a new way to measure heart damage caused by certain breast cancer treatments may find damage earlier than traditional measurement tests.
-
Axillary Lymph Node Removal May Not Make Sense for Most Women
Research suggests that routinely removing multiple underarm (axillary) lymph nodes during early-stage breast cancer surgery may not make sense for most women.
-
HER2-Positive Breast Cancer May Respond to Experimental Treatments
Early results from a very early study suggests that some advanced-stage, HER2-positive breast cancers that have stopped responding to Herceptin may respond to the experimental treatment T-DM1.
-
Olaparib May Help Treat Triple-Negative Breast Cancer
Research suggests that combining the experimental targeted therapy olaparib with a taxane chemotherapy may be effective against triple-negative breast cancer.
-
Biopsy of Metastatic Cancer May Change Treatment Plan
Research suggests that a breast cancer's characteristics may change if the cancer metastasizes, so doing a biopsy on metastatic cancer may make sense in some cases.
-
Adding Avastin to Chemo Stops Metastatic Cancer From Growing
Adding Avastin to any of several common chemotherapy regimens for metastatic, HER2-negative breast cancer seems to lengthen the time before the cancer grows compared to the same regimen without Avastin.
